These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 24732904

  • 1. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M, Florek A, Zaucha JM, Chmielowska E, Giza A, Knopinska-Posluszny W, Kulikowski W, Prejzner W, Romejko-Jarosinska J, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Rogowski W, Grzanka A, Placek W, Lugowska-Umer H, Kowalczyk A, Nowicki R, Jurczak W.
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [Abstract] [Full Text] [Related]

  • 2. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [Abstract] [Full Text] [Related]

  • 3. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M.
    J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP, Levitan D, Fleischer AB.
    J Dermatolog Treat; 2009 Nov; 20(3):169-76. PubMed ID: 19016373
    [Abstract] [Full Text] [Related]

  • 5. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK, Lebwohl M.
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [Abstract] [Full Text] [Related]

  • 6. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    Väkevä L, Ranki A, Hahtola S.
    Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
    [Abstract] [Full Text] [Related]

  • 7. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 8. [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
    Rodriguez Suarez S, Pamies Andreu E, Muñiz Grijalvo O, Garcia Morillo JS.
    Med Clin (Barc); 2016 Feb 05; 146(3):117-20. PubMed ID: 26688184
    [Abstract] [Full Text] [Related]

  • 9. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S.
    Br J Dermatol; 2006 Aug 05; 155(2):261-6. PubMed ID: 16882161
    [Abstract] [Full Text] [Related]

  • 10. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
    Izu-Belloso R, Gainza-Apraiz I, Ortiz-Romero P, Servitje-Bedate O, Fernández de Misa-Cabrera R, Peñate Y, Hernandez-Machin B, Estrach-Panella T, Llamas-Velasco M, Yanguas-Bayona JI, Morillo-Andujar M, Acebo-Mariñas E, Perez-Gala S, Armario-Hita JC, Sanchez-Sambucety P, Ortiz-Brugues A, Eguren-Michelena C, Bielsa-Marsol I, Lopez-Pestaña A, Blanes-Martinez M, Fernandez-Guarino M, Lopez-Lerma I.
    Actas Dermosifiliogr; 2024 Jun 05; 115(6):547-554. PubMed ID: 38395224
    [Abstract] [Full Text] [Related]

  • 11. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
    Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ.
    Arch Dermatol; 2002 Mar 05; 138(3):325-32. PubMed ID: 11902983
    [Abstract] [Full Text] [Related]

  • 12. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC, Quéreux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, Dréno B.
    Exp Dermatol; 2010 Aug 05; 19(8):e95-102. PubMed ID: 19845755
    [Abstract] [Full Text] [Related]

  • 13. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
    Rupoli S, Canafoglia L, Goteri G, Leoni P, Brandozzi G, Federici I, Micucci G, Giantomassi F, Mozzicafreddo G, Alterini R, Filosa G, Ricotti G, Simonacci M, Scortechini AR, Zizzi A, Pimpinelli N.
    Eur J Dermatol; 2016 Aug 05; 26(1):13-20. PubMed ID: 26678311
    [Abstract] [Full Text] [Related]

  • 14. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA, Davis MD, el-Azhary RA, McEvoy MT, Gibson LE, Knudsen JM, Kist JM, Pittelkow MR.
    J Am Acad Dermatol; 2005 Jun 05; 52(6):991-6. PubMed ID: 15928617
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma.
    Huen AO, Kim EJ.
    Dermatol Clin; 2015 Oct 05; 33(4):715-29. PubMed ID: 26433844
    [Abstract] [Full Text] [Related]

  • 18. Acitretin for the treatment of cutaneous T-cell lymphoma.
    Cheeley J, Sahn RE, DeLong LK, Parker SR.
    J Am Acad Dermatol; 2013 Feb 05; 68(2):247-54. PubMed ID: 22917895
    [Abstract] [Full Text] [Related]

  • 19. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
    Lewis DJ, Huang S, Duvic M.
    Dermatol Ther; 2017 Sep 05; 30(5):. PubMed ID: 28748653
    [Abstract] [Full Text] [Related]

  • 20. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
    Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC, Bexarotene Worldwide Study Group.
    J Clin Oncol; 2001 May 01; 19(9):2456-71. PubMed ID: 11331325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.